Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ADH5 | P11766 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528958 | 0.79 | KDM4E (0.51) | TTRRARBRORCCYP2C9MYC | |
| SCHEMBL1929432 | 0.78 | POLB (0.42) | ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL3530849 | 0.76 | NR2E1 (0.45) | TTRADH5 | |
| SCHEMBL5111436 | 0.71 | RORC (0.39) | TTRRORCMYCESR1ALOX15 | |
| SCHEMBL5100509 | 0.71 | TTR (0.41) | TTRRBP4RORCMYCESR1 | |
| SCHEMBL374174 | 0.70 | TAS2R14 (0.50) | TTRRARBMYCESR1ALOX15 | |
| SCHEMBL29528380 | 0.70 | TAS2R14 (0.50) | TTRRARBMYCESR1ALOX15 | |
| SCHEMBL27635758 | 0.70 | TTR (0.47) | TTRRORCCYP2C9ADH5 | |
| SCHEMBL31309600 | 0.70 | GRM5 (0.37) | TTRRBP4RARBSORT1 | |
| SCHEMBL15974524 | 0.70 | KDM4C (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| CN-100404528-C | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1684951-A | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | TTR 3121/4885RBP4 3882/4885RARB 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.